scispace - formally typeset
Search or ask a question
Institution

Guy's and St Thomas' NHS Foundation Trust

HealthcareLondon, United Kingdom
About: Guy's and St Thomas' NHS Foundation Trust is a healthcare organization based out in London, United Kingdom. It is known for research contribution in the topics: Population & Randomized controlled trial. The organization has 7686 authors who have published 9631 publications receiving 399353 citations. The organization is also known as: Guy's and St Thomas' National Health Service Foundation Trust & Guy's and St Thomas' National Health Service Trust.


Papers
More filters
Journal ArticleDOI
TL;DR: Preliminary evidence is demonstrated that specific polymorphisms of enzymes involved in folate, pyrimidine, and purine metabolism could be useful in predicting clinical response to methotrexate in patients with psoriasis.

113 citations

Journal ArticleDOI
TL;DR: This review attempts to highlight the cellular components that can be targeted, within the excitation-contraction coupling cascade, to induce cardiac arrest, and to provide an explanation for the mechanism of action of these agents.

113 citations

Journal ArticleDOI
Mia M. Gaudet1, Karoline Kuchenbaecker2, Joseph Vijai3, Robert J. Klein3, Tomas Kirchhoff4, Lesley McGuffog2, Daniel Barrowdale2, Alison M. Dunning2, Andy C. H. Lee2, Joe Dennis2, Sue Healey5, Ed Dicks2, Penny Soucy6, Olga M. Sinilnikova7, Vernon S. Pankratz8, Xianshu Wang8, Ronald C. Eldridge9, Daniel C. Tessier10, Daniel Vincent10, Francois Bacot10, Frans B. L. Hogervorst11, Susan Peock2, Dominique Stoppa-Lyonnet12, Dominique Stoppa-Lyonnet13, kConFab Investigators14, Paolo Peterlongo, Rita K. Schmutzler, Katherine L. Nathanson15, Marion Piedmonte16, Christian F. Singer17, Mads Thomassen18, Thomas Hansen19, Susan L. Neuhausen20, Ignacio Blanco, Mark H. Greene21, Judith Garber22, Jeffrey N. Weitzel23, Irene L. Andrulis24, Irene L. Andrulis25, David E. Goldgar26, Emma D'Andrea27, Trinidad Caldés28, Heli Nevanlinna29, Ana Osorio, Elizabeth J. van Rensburg30, Adalgeir Arason31, Gad Rennert32, Ans M.W. van den Ouweland33, Annemarie H. van der Hout34, Carolien M. Kets35, Cora M. Aalfs, Juul T. Wijnen36, Margreet G. E. M. Ausems37, Hebon11, Embrace2, Debra Frost2, Steve Ellis2, Elena Fineberg2, Radka Platte2, D. Gareth Evans2, Chris Jacobs38, Julian Adlard, Marc Tischkowitz2, Mary Porteous39, Francesca Damiola7, Lisa Golmard13, Laure Barjhoux7, Michel Longy40, Muriel Belotti13, Sandra Fert Ferrer, Sylvie Mazoyer7, Amanda B. Spurdle5, Siranoush Manoukian, Monica Barile, Maurizio Genuardi41, Norbert Arnold42, Alfons Meindl43, Christian Sutter44, Barbara Wappenschmidt, Susan M. Domchek15, Georg Pfeiler17, Eitan Friedman45, Uffe Birk Jensen46, Mark E. Robson3, Sohela Shah3, Conxi Lázaro, Phuong L. Mai21, Javier Benitez, Melissa C. Southey47, Marjanka K. Schmidt11, Peter A. Fasching48, Julian Peto49, Manjeet K. Humphreys2, Qin Wang2, Kyriaki Michailidou2, Elinor J. Sawyer38, Barbara Burwinkel50, Barbara Burwinkel44, Pascal Guénel51, Pascal Guénel52, Stig E. Bojesen19, Roger L. Milne, Hermann Brenner50, Magdalena Lochmann43, Kristiina Aittomäki29, Thilo Dörk53, Sara Margolin54, Arto Mannermaa55, Diether Lambrechts56, Jenny Chang-Claude50, Paolo Radice, Graham G. Giles47, Graham G. Giles57, Christopher A. Haiman58, Robert Winqvist59, Peter Devillee36, Montserrat Garcia-Closas60, Montserrat Garcia-Closas61, Nils Schoof54, Maartje J. Hooning33, Angela Cox62, Paul D.P. Pharoah2, Anna Jakubowska63, Nick Orr61, Anna González-Neira, Guillermo Pita, M. Rosario Alonso, Per Hall61, Fergus J. Couch8, Jacques Simard6, David Altshuler64, David Altshuler65, Douglas F. Easton2, Georgia Chenevix-Trench5, Antonis C. Antoniou2, Kenneth Offit3 
American Cancer Society1, University of Cambridge2, Memorial Sloan Kettering Cancer Center3, New York University4, QIMR Berghofer Medical Research Institute5, Laval University6, University of Lyon7, Mayo Clinic8, Emory University9, McGill University10, Netherlands Cancer Institute11, Paris Descartes University12, Curie Institute13, Peter MacCallum Cancer Centre14, University of Pennsylvania15, Roswell Park Cancer Institute16, Medical University of Vienna17, Odense University Hospital18, Copenhagen University Hospital19, Beckman Research Institute20, National Institutes of Health21, Dana Corporation22, City of Hope National Medical Center23, Mount Sinai Hospital, Toronto24, University of Toronto25, University of Utah26, University of Padua27, Hospital Clínico San Carlos28, Helsinki University Central Hospital29, University of Pretoria30, University of Iceland31, Rappaport Faculty of Medicine32, Erasmus University Medical Center33, University Medical Center Groningen34, Radboud University Nijmegen Medical Centre35, Leiden University Medical Center36, Utrecht University37, Guy's and St Thomas' NHS Foundation Trust38, Western General Hospital39, University of Bordeaux40, University of Florence41, University of Kiel42, Technische Universität München43, Heidelberg University44, Sheba Medical Center45, Aarhus University Hospital46, University of Melbourne47, University of California, Los Angeles48, University of London49, German Cancer Research Center50, French Institute of Health and Medical Research51, University of Paris-Sud52, Hannover Medical School53, Karolinska Institutet54, University of Eastern Finland55, Katholieke Universiteit Leuven56, Cancer Council Victoria57, University of Southern California58, Oulu University Hospital59, Institute of Cancer Research60, The Breast Cancer Research Foundation61, University of Sheffield62, Pomeranian Medical University63, Broad Institute64, Harvard University65
TL;DR: A comprehensive update of novel and previously reported breast cancer susceptibility loci contributes to the establishment of a panel of SNPs that modify breast cancer risk in BRCA2 mutation carriers and may have clinical utility for women with BRCa2 mutations weighing options for medical prevention of breast cancer.
Abstract: Common genetic variants contribute to the observed variation in breast cancer risk for BRCA2 mutation carriers; those known to date have all been found through population-based genome-wide association studies (GWAS). To comprehensively identify breast cancer risk modifying loci for BRCA2 mutation carriers, we conducted a deep replication of an ongoing GWAS discovery study. Using the ranked P-values of the breast cancer associations with the imputed genotype of 1.4 M SNPs, 19,029 SNPs were selected and designed for inclusion on a custom Illumina array that included a total of 211,155 SNPs as part of a multi-consortial project. DNA samples from 3,881 breast cancer affected and 4,330 unaffected BRCA2 mutation carriers from 47 studies belonging to the Consortium of Investigators of Modifiers of BRCA1/2 were genotyped and available for analysis. We replicated previously reported breast cancer susceptibility alleles in these BRCA2 mutation carriers and for several regions (including FGFR2, MAP3K1, CDKN2A/B, and PTHLH) identified SNPs that have stronger evidence of association than those previously published. We also identified a novel susceptibility allele at 6p24 that was inversely associated with risk in BRCA2 mutation carriers (rs9348512; per allele HR = 0.85, 95% CI 0.80-0.90, P = 3.9 x 10(-8)). This SNP was not associated with breast cancer risk either in the general population or in BRCA1 mutation carriers. The locus lies within a region containing TFAP2A, which encodes a transcriptional activation protein that interacts with several tumor suppressor genes. This report identifies the first breast cancer risk locus specific to a BRCA2 mutation background. This comprehensive update of novel and previously reported breast cancer susceptibility loci contributes to the establishment of a panel of SNPs that modify breast cancer risk in BRCA2 mutation carriers. This panel may have clinical utility for women with BRCA2 mutations weighing options for medical prevention of breast cancer.

113 citations

Journal ArticleDOI
01 Jun 2005-Apmis
TL;DR: The more widespread recognition by histopathologists of the pattern of injury manifested by increased numbers of IELs in intestinal biopsy specimens will certainly help in early diagnosis of coeliac disease, lessen diagnostic confusion and influence the modern practice of gastrointestinal tract medicine.
Abstract: Intestinal intraepithelial lymphocytes (IELs) belong to a unique T-cell population interspersed between epithelial cells of both the small and large intestine. It is becoming increasingly recognised that an increased number of IELs with a normal villous architecture is within the wide spectrum of histological abnormalities observed in coeliac disease. An increased number of IELs is the earliest pathological change following gluten challenge and a high IEL count may be the only sign of gluten sensitivity. Therefore, the finding of a raised IEL count with normal villous architecture is of sufficient clinical importance to be reported in routine small bowel biopsies. However, it is evident that not all small intestinal biopsy specimens showing increased IELs are explained by gluten sensitivity. Increased IELs in small bowel mucosa have also been associated with autoimmune disorders, tropical sprue, food protein intolerance, Helicobacter pylori-associated gastritis, peptic duodenitis, parasitic and viral infections, as well as the development of intestinal lymphoma. Histological examination of a biopsy specimen of the small bowel remains the diagnostic gold standard for coeliac disease. There will be an ever increasing demand for histological confirmation of gluten sensitivity in patients in whom the classic microscopic appearance of flattened villi may not have fully developed. The more widespread recognition by histopathologists of the pattern of injury manifested by increased numbers of IELs in intestinal biopsy specimens will certainly help in early diagnosis of coeliac disease, lessen diagnostic confusion and influence the modern practice of gastrointestinal tract medicine. This review discusses some of the recent developments in clinical pathology pertaining to increased IELs in small bowel mucosal biopsies.

113 citations

Journal ArticleDOI
TL;DR: The cadaveric study demonstrates that injection of dye on the posterior aspect of quadratus lumborum muscle led to injectate spread through the lateral and posterior abdominal wall but with limited cranial spread, whereas the anterior approach produced broader coverage of the lower to mid-thoracic region.
Abstract: BACKGROUNDThe dermatomal level of analgesia achieved with quadratus lumborum blocks varies according to the location of injection. The most commonly used approaches are either at the postero-lateral aspect or anterior to the quadratus lumborum muscle.OBJECTIVETo determine whether the site of injecti

113 citations


Authors

Showing all 7765 results

NameH-indexPapersCitations
Christopher J L Murray209754310329
Bruce M. Psaty1811205138244
Giuseppe Remuzzi1721226160440
Mika Kivimäki1661515141468
Simon I. Hay165557153307
Theo Vos156502186409
Ali H. Mokdad156634160599
Steven Williams144137586712
Igor Rudan142658103659
Mohsen Naghavi139381169048
Christopher D.M. Fletcher13867482484
Martin McKee1381732125972
David A. Jackson136109568352
Graham G. Giles136124980038
Yang Liu1292506122380
Network Information
Related Institutions (5)
University Medical Center Groningen
30.3K papers, 967K citations

93% related

Royal Free Hospital
15.7K papers, 651.9K citations

93% related

John Radcliffe Hospital
23.6K papers, 1.4M citations

92% related

Radboud University Nijmegen Medical Centre
12.6K papers, 659.2K citations

92% related

Leiden University Medical Center
38K papers, 1.6M citations

92% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
202316
202298
20211,488
20201,123
2019829
2018767